title: The effect of hormone replacement therapy on bone mass in patients with ovarian failure due to bone marrow transplantation.
abstract: BACKGROUND
  Long permanent remissions in malignant hematopoietic disorders can often be achieved by autologous bone marrow transplantation (ABMT) or by allogenic bone marrow transplantation (BMT). Previous studies have shown that such therapies may induce osteoporosis due to iatrogenic ovarian failure. The administration of hormone replacement therapy (HRT) in these women could prevent the adverse effects of long-term ovarian failure without remarkable side effects. The aim of this study was to evaluate how the bone mass is affected by HRT in patients undergoing ABMT or BMT adjusting the results for age, weight, and height.
  
  
  METHODS
  Thirteen women with previous ABMT/BMT were treated with a standard dose (0.625 mg/day) of conjugated equine estrogen (CEE) or with 50 micrograms/day of 17-beta-estradiol in transdermal therapeutic systems (TTS) plus 5 mg/day of medroxyprogesterone acetate sequentially added to the last 12 days of estrogen therapy. Bone mass was measured prior to and 12 months following HRT. Blood samples were collected before therapy and during the 6th and 12th treatment months.
  
  
  RESULTS
  The mean time elapsed between bone transplantation and HRT initiation was 13.0 months (range 3-26 months). Before treatment nine patients were osteopenic and after HRT bone mass increased in all cases. Following ABMT/BMT, hepatic hyperenzymemia was detected in three patients. After 6 and 12 months of treatment no significant changes were observed in hepatic enzymes.
  
  
  CONCLUSIONS
  Although hepatic hyperenzymemia is commonly considered as a contraindication for HRT, our results suggest that HRT is safe for these patients and that such therapy should be initiated after transplantation in women to prevent adverse effects of long-term ovarian failure.
authors.affiliation: Department of Gynecology & Obstetrics, Menopause Clinic, Barcelona, Spain.
authors.forename: C
authors.initials: C
authors.lastname: Castelo-Branco
authors.forename: M
authors.initials: M
authors.lastname: Rovira
authors.forename: F
authors.initials: F
authors.lastname: Pons
authors.forename: M
authors.initials: M
authors.lastname: Durán
authors.forename: J
authors.initials: J
authors.lastname: Sierra
authors.forename: A
authors.initials: A
authors.lastname: Vives
authors.forename: J
authors.initials: J
authors.lastname: Balasch
authors.forename: A
authors.initials: A
authors.lastname: Fortuny
authors.forename: J
authors.initials: J
authors.lastname: Vanrell
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D015519:Bone Density / Q000187:drug effects*; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D004958:Estradiol / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use; D005260:Female; D019337:Hematologic Neoplasms / Q000628:therapy; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use; D010024:Osteoporosis / Q000517:prevention & control*; D016649:Primary Ovarian Insufficiency / Q000209:etiology*; D045167:Progesterone Congeners / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D004966:Estrogens, Conjugated (USP); D045167:Progesterone Congeners; D004958:Estradiol; D017258:Medroxyprogesterone Acetate